EORTC selected abstracts at ASCO 2021
4 Jun 2021
ASCO Annual Meeting will take place virtually from 4 to 8 June 2021.
7 EORTC abstracts were accepted for the conference.
Oral sessions
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
Date: Sunday 6 June, 14:00-17:00 CEST
Abstract number: 9500
Authors: Alexander M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U. Blank, Mario Mandala, Georgina V. Long, Catherine Barrow, Anna Maria Di Giacomo, Rosalie Stephens, Shahneen Kaur Sandhu, Ragini Reiney Kudchadkar, Pablo L. Ortiz-Romero, Inge Marie Svane, Alexander Christopher Jonathan Van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert
Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial
Date: Sunday 6 June, 14:00-17:00 CEST
Abstract number: 500
Authors: Josephine Lopes Cardozo, Caroline Drukker, Marjanka Schmidt, Laura van ‘t Veer, Annuska Glas, A. Witteveen, Fatima Cardoso, Martine J. Piccart-Gebhart, Coralie Poncet, Emiel J. Rutgers
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
Date: Monday 7 June, 14:00-17:00 CEST
Abstract number: 2400
Authors: Patrick Roth, Thierry Gorlia, Jaap C. Reijneveld, Filip Yves Francine Leon De Vos, Ahmed ldbaih, JeanSebastien Frenel, Emilie Le Rhun, Jose Manuel Sepulveda Sanchez, James R. Perry, Laura Masucci, Pierre Freres, Hal W. Hirte, Clemens Seidel, Anna Maria Elisabeth Walenkamp, Frederic Dhermain, Martin J. Van Den Bent, Christopher J. O’Callaghan, Maureen Vanlancker, Warren P. Mason, Michael Weller
Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII Trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis
Date: Tuesday 8 June, 14:00-17:00 CEST
Abstract number: 5002
Authors: Silke Gillessen, Ananya Choudhury, Alejo Rodriguez-Vida, Franco Nole, Enrique Gallardo Diaz, Thierry Andre Roumeguere, Gedske Daugaard, Yohann Lariat, Fred Saad, Raymond S. McDermott, Anouk Neven, Beatrice Fournier, Bertrand F. Tombal
Poster sessions
Critical impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial
Date: Friday 4 June
Abstract number: 11566
Authors: Rick L.M. Haas, Jean-Jacques Stelmes, Facundo Zaffaroni, Enrico Clemente!, Raquel Bar Deroma, Cecile Le Pechoux, Saskia Litiere, Sandrine Marreaud, Najlaa Alyamani, Nicolaus Andratschke, Claudia Sangalli, Peter W. M. Chung, Aisha Miah, Coen Hurkmans, Alessandro Gronchi, Judith V.M.G. Bovee, Hans Gelderblom, Bernd Kasper, Damien Weber, Sylvie Bonvalot
Updated results of EORTC Phase II trial of Cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma
Date: Friday 4 June
Abstract number: 11518
Authors: Roberta Sanfilippo, Richard L Hayward, Jammbe Musoro, Charlotte Benson, Michael Gordon Leahy, Antonella Brunello,Jean-Yves Blay, Neeltje Steeghs, Ingrid Desar, Nasim Ali, Alice Hervieu, Khin Thway, Sandrine Marreaud, Saskia Litiere, Bernd Kasper
Online publication
Coverage of symptomatic toxicities from the common terminology criteria for adverse events (CTCAE) framework within the European Organization for Research and Treatment of Cancer (EORTC) item library.
Abstract number: e24117
Authors: Claire Piccinin, Andrew Bottomley, Galina Velikova, Mogens Groenvold, Dagmara Kulis, Jane M. Blazeby, Alexandra Gilbert
More information on the 2021 ASCO Annual Conference website.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023